STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease

Cytokine and Growth Factor Reviews

Volumn 22, Issue 4, 2011, Pages 211-219

  Sikorski, Krzysztof ^a   Czerwoniec, Anna ^a   Bujnicki, Janusz M ^a,b   Wesoly, Joanna ^a   Bluyssen, Hans A R ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

Author keywords

Atherosclerosis; IFN ; IL 6; SOCS; STAT1; Therapeutical target; TLR4

Indexed keywords

CYCLOSPORIN A; DRUG METABOLITE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 6; OLIGONUCLEOTIDE; PATTERN RECOGNITION RECEPTOR; PHOSPHOTYROSINE; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL; CELL ADHESION; DISEASE COURSE; DRUG TARGETING; ENDOTHELIUM CELL; FOAM CELL; HEMATOLOGIC MALIGNANCY; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INJURY; INNATE IMMUNITY; LEUKOCYTE; LEUKOCYTE MIGRATION; MOLECULAR INTERACTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; UPREGULATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 81155131139     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.06.003     Document Type: Review

References (82)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Hack C.E., Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001, 29:S21-S27.
3. Robertson A.K., Hansson G.K. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol 2006, 26:2421-2432.
4. Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006, 1:297-329.
5. Hidalgo L.G., Halloran P.F. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002, 22:317-349.
6. Leon M.L., Zuckerman S.H. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res 2005, 54:395-411.
7. Tellides G., Tereb D.A., Kirkiles-Smith N.C., Kim R.W., Wilson J.H., Schechner J.S., et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000, 403:207-211.
8. McLaren J.E., Ramji D.P. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009, 20:125-135.
9. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007, 282:20047-20051.
10. Wesoly J., Szweykowska-Kulinska Z., Bluyssen H.A. STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim Pol 2007, 54:27-38.
11. Levy D.E., Darnell J..E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662.
12. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFN gamma signaling-does it mean JAK-STAT?. Cytokine Growth Factor Rev 2008, 19:383-394.
13. Bluyssen A.R., Durbin J.E., Levy D.E. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev 1996, 7:11-17.
14. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
15. Tsan M.F., Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004, 76:514-519.
16. Bjorkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 2006, 17:527-533.
17. Dasu M.R., Riosvelasco A.C., Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2009, 202:76-83.
18. Frantz S., Ertl G., Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007, 4:444-454.
19. Hertzog P.J., O'Neill L.A., Hamilton J.A. The interferon in TLR signaling: more than just antiviral. Trends Immunol 2003, 24:534-539.
20. Sikorski K., Chmielewski S., Przybyl L., et al. STAT1-mediated signal integration between IFN{gamma} and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol 2011, 300:C1334-C1337.
21. Schroder K., Sweet M.J., Hume D.A. Signal integration between IFN gamma and TLR signalling pathways in macrophages. Immunobiology 2006, 211:511-524.
22. Hu X., Chen J., Wang L., Ivashkiv L.B. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 2007, 82:237-243.
23. Hu X., Chakravarty S.D., Ivashkiv L.B. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008, 226:41-56.
24. Hu X., Ivashkiv L.B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009, 31:539-550.
25. Zhao J., Kong H.J., Li H., Huang B., Yang M., Zhu C., et al. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J Biol Chem 2006, 281:10073-10080.
26. Negishi H., Fujita Y., Yanai H., Sakaguchi S., Ouyang X., Shinohara M., et al. Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc Natl Acad Sci USA 2006, 103:15136-15141.
27. Doran A.C., Meller N., McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:812-819.
28. Lawson C., Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009, 61:22-32.
29. Heller E.A., Liu E., Tager A.M., Yuan Q., Lin A.Y., Ahluwalia N., et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006, 113:2301-2312.
30. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999, 104:1041-1050.
31. Alexander W.S., Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004, 22:503-529.
32. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7:454-465.
33. Wesoly J., Sikorski K., Lee C.K., Bluyssen H.A. Suppressor of cytokine signaling and accelerated atherosclerosis in kidney disease. Acta Biochim Pol 2010, 57:251-260.
34. Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J., et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006, 7:148-155.
35. Naka T., Matsumoto T., Narazaki M., Fujimoto M., Morita Y., Ohsawa Y., et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 1998, 95:15577-15582.
36. Starr R., Metcalf D., Elefanty A.G., Brysha M., Willson T.A., Nicola N.A., et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 1998, 95:14395-14399.
37. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999, 18:1309-1320.
38. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000, 97:6493-6498.
39. Takahashi Y., Carpino N., Cross J.C., Torres M., Parganas E., Ihle J.N. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J 2003, 22:372-384.
40. Kimura A., Kinjyo I., Matsumura Y., Mori H., Mashima R., Harada M. SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling. J Biol Chem 2004, 279:6905-6910.
41. Nakagawa R., Naka T., Tsutsui H., Fujimoto M., Kimura A., Abe T., et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002, 17:677-687.
42. Marine J.C., McKay C., Wang D., Topham D.J., Parganas E., Nakajima H., et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999, 98:617-627.
43. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 2001, 98:9324-9329.
44. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003, 4:540-545.
45. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003, 4:546-550.
46. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003, 4:551-556.
47. Mori H., Hanada R., Hanada T., Aki D., Mashima R., Nishinakamura H., et al. SOCS3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004, 10:739-743.
48. Croker B.A., Metcalf D., Robb L., Wei W., Mifsud S., DiRago L., et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004, 20:153-165.
49. Chen Y., Chong M.M., Darwiche R., Thomas H.E., Kay T.W. Severe pancreatitis with exocrine destruction and increased islet neogenesis in mice with suppressor of cytokine signaling-1 deficiency. Am J Pathol 2004, 165:913-921.
50. Fujimoto M., Tsutsui H., Xinshou O., Tokumoto M., Watanabe D., Shima Y., et al. Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol 2004, 16:303-314.
51. Niemand C., Nimmesgern A., Haan S., Fischer P., Schaper F., Rossaint R., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003, 170:3263-3272.
52. Suzuki A., Hanada T., Mitsuyama K., Yoshida T., Kamizono S., Hoshino T., et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001, 193:471-481.
53. Tang J., Raines E.W. Are suppressors of cytokine signaling proteins recently identified in atherosclerosis possible therapeutic targets?. Trends Cardiovasc Med 2005, 15:243-249.
54. Nawawi H., Osman N.S., Annuar R., Khalid B.A., Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003, 169:283-291.
55. Stenvinkel P. Endothelial dysfunction and inflammation - is there a link?. Nephrol Dial Transplant 2001, 16:1968-1971.
56. Stenvinkel P., Heimburger O., Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002, 39:274-282.
57. Aderka D., Le J.M., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989, 143:3517-3523.
58. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999, 19:2364-2367.
59. Schieffer B., Selle T., Hilfiker A., Hilfiker-Kleiner D., Grote K., Tietge U.J., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 2004, 110:3493-3500.
60. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311-320.
61. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890.
62. Yuan J., Wegenka U.M., Lütticken C., Buschmann J., Decker T., Schindler C., et al. The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol 1994, 14:1657-1668.
63. Guschin D., Rogers N., Briscoe J., Witthuhn B., Watling D., Horn F., et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 1995, 14:1421-1429.
64. Stahl N., Boulton T.G., Farruggella T., Ip N.Y., Davis S., Witthuhn B.A., et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994, 263:92-95.
65. Akira S., Nishio Y., Inoue M., Wang X.J., Wei S., Matsusaka T., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63-71.
66. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
67. Ihle J.N. The STAT family in cytokine signaling. CurrOpin Cell Biol 2001, 13:211-217.
68. Stephanou A., Latchman D.S. Opposing actions of STAT-1 and STAT-3. Growth Factors 2005, 23:177-182.
69. Costa-Pereira A.P., Tininini S., Strobl B., Alonzi T., Schlaak J.F., Is'harc H., et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci USA 2002, 99:8043-8047.
70. Bluyssen H.A., Rastmanesh M.M., Tilburgs C., Jie K., Wesseling S., Goumans M.J., et al. IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol 2010, 299:C354-C362.
71. Bode J.G., Nimmesgern A., Schmitz J., Schaper F., Schmitt M., Frisch W., et al. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett 1999, 463:365-370.
72. Agrawal S., Febbraio M., Podrez E., Cathcart M.K., Stark G.R., Chisolm G.M. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 2007, 115:2939-2947.
73. Hölschermann H., Stadlbauer T.H., Wagner A.H., Fingerhuth H., Muth H., Rong S., et al. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res 2006, 71:527-536.
74. Stojanovic T., Scheele L., Wagner A.H., Middel P., Bedke J., Lautenschläger I., et al. STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. Gene Ther 2007, 14:883-890.
75. Frank D.A., Mahajan S., Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999, 5:444-447.
76. Torella D., Curcio A., Gasparri C., Galuppo V., De Serio D., Surace F.C., et al. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am J Physiol Heart Circ Physiol 2007, 292:H2935-H2943.
77. Gandhi V., Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002, 41:93-103.
78. Woodahl E.L., Wang J., Heimfeld S., Sandmaier B.M., O'Donnell P.V., Phillips B., et al. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemother Pharmacol 2009, 63:391-401.
79. Chen X., Vinkemeier U., Zhao Y., Jeruzalmi D., Darnell J..E., Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998, 93:827-839.
80. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007, 13:1362-1366.
81. Lang P.T., Brozell S.R., Mukherjee S., Pettersen E.F., Meng E.C., Thomas V., et al. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 2009, 15:1219-1230.
82. Jain A.N. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 2007, 21:281-306.